Nurix Therapeutics, Inc.

NRIX • Biotechnology

$26.14

▲ +0.82 (+3.24%)

Precio actual

ResultadosÚltimo reporte: 28 feb 2026

PERFIL DE MAYOR RIESGOPrecauciónConfianza: 70%

Perfil cuantitativo — no constituye una recomendación de inversión.

Perfil cuantitativo — no constituye una recomendación de inversión.Metodología

Tesis del análisis: Conviene actuar con cautela. Los ratios recientes muestran debilidades que pueden limitar el retorno si los fundamentales no mejoran.

Capitalización

$2.88B

Crecimiento

-11.8%

Flujo de caja

0/5

Tendencia

Negative

Evidencia

Crecimiento positivo de ingresos · 8.7%Nivel de deuda manejable · 0.1Liquidez saludable · 7.02Rentabilidad débil

Datos financieros hasta: 28 feb 2026, 12:00 a.m. UTCÚltima actualización de earnings: 8 abr 2026, 12:00 a.m. UTCÚltima actualización del perfil: 5 ago 2026, 2:36 p.m. UTC

Resumen de la compañía

Valoración, calidad, fortaleza financiera, momentum y datos de analistas.

Price$26.14

Change3.24%

Shares Out110.07M

Market Cap$2.88B

Enterprise Value$2.34B

52W Range8.20 - 23.09

Beta1.87

P/E-9.74

P/S40.09

P/B5.98

P/FCF-10.58

EV/Sales32.55

Price$26.14

Change3.24%

Shares Out110.07M

Market Cap$2.88B

Enterprise Value$2.34B

52W Range8.20 - 23.09

Beta1.87

P/E-9.74

P/S40.09

P/B5.98

P/FCF-10.58

EV/Sales32.55

EV/EBITDA-8.09

EV/FCF-8.59

Earnings Yield-10.26%

FCF Yield-9.45%

Dividend Yield0.00%

Gross Margin77.55%

Oper. Margin-3.40%

Profit Margin-3.15%

Debt/Eq0.10

Current Ratio7.02

Quick Ratio7.02

Revenue 5Y-11.75%

Target$34.67

Target Upside32.63%

Target Median$34.00

Target Range28.00 - 45.00

Volume5.33M

Avg Volume1.78M

EPS Surprise-0.03

ADN de inversión

Qué tan fuerte luce esta compañía para inversionistas de largo plazo

de 100

Calidad del negocio

Márgenes, ventaja competitiva, retornos

22/100

Fortaleza financiera

Deuda, caja, estabilidad

76/100

Potencial de crecimiento

Ingresos y expansión

89/100

Atractivo del precio

Barata o cara hoy

50/100

Por qué este puntaje▼

Crecimiento positivo de ingresos · 8.7%Nivel de deuda manejable · 0.1Liquidez saludable · 7.02Rentabilidad débil

Analyst view

Analyst sentiment and price target

NRIX

Analyst sentiment

Based on 19 analyst votes · 2026-09-05

100/100

Bullish

Hold

Bearish

Precio objetivo

2026-06-26

Bajo

$23.00

Promedio

$33.00

Mediana

$32.50

Alto

$45.00

Resumen de la compañía

IPO: 7/24/2020

Industria: Biotechnology

P/B i: 5.98

Deuda / Patrimonio i: 0.10

Margen operativo: -340.16%

Margen neto: -314.90%

ROE i: -

ROIC: -

Salud financiera

Puntaje15 / 20

Deuda / Patrimonio: 0.10

Ratio corriente: 7.02

Ratio rápido: 7.02

Estado: Good

Transacciones internas

Actividad reciente de ejecutivos e insiders

Ring Christine

Transacción: 06/25/2026

VENTA

Cambio

-28,935

Precio

$20.06

Presentación

06/25/2026

Tipo

VENTA

Ring Christine

Transacción: 06/25/2026

VENTA

Cambio

-13,333

Precio

$7.26

Presentación

06/25/2026

Tipo

VENTA

Hansen Gwenn

Transacción: 06/25/2026

VENTA

Cambio

-5,394

Precio

$20.00

Presentación

06/25/2026

Tipo

VENTA

Insider	Tipo	Cambio	Precio	Transacción	Presentación
Ring Christine	VENTA	-28,935	$20.06	06/25/2026	06/25/2026
Ring Christine	VENTA	-13,333	$7.26	06/25/2026	06/25/2026
Hansen Gwenn	VENTA	-5,394	$20.00	06/25/2026	06/25/2026
Ring Christine	VENTA	-3,422	$1.86	06/02/2026	06/02/2026
Ring Christine	VENTA	-8,148	$16.60	06/02/2026	06/02/2026
GREGORY JULIA P	COMPRA	+31,250	$15.86	05/15/2026	05/15/2026
Baynes Roy D.	COMPRA	+31,250	$15.86	05/15/2026	05/15/2026
DANSEY ROGER D	COMPRA	+31,250	$15.86	05/15/2026	05/15/2026
Kapur Anil	COMPRA	+31,250	$15.86	05/15/2026	05/15/2026
Lacey David L.	COMPRA	+31,250	$15.86	05/15/2026	05/15/2026
Reinsdorf Judith A	COMPRA	+31,250	$15.86	05/15/2026	05/15/2026
Saltzman Edward C	COMPRA	+31,250	$15.86	05/15/2026	05/15/2026
Silva Paul M	COMPRA	+31,250	$15.86	05/15/2026	05/15/2026
van Houte Hans	VENTA	-582	$17.18	05/05/2026	05/05/2026
Ring Christine	VENTA	-8,148	$16.96	05/04/2026	05/04/2026
Ring Christine	VENTA	-5,394	$16.76	05/01/2026	05/01/2026
Hansen Gwenn	VENTA	-2,000	Not reported	04/30/2026	04/30/2026
Hansen Gwenn	COMPRA	+2,000	Not reported	04/30/2026	04/30/2026
Ring Christine	VENTA	-2,000	Not reported	04/30/2026	04/30/2026
Ring Christine	COMPRA	+2,000	Not reported	04/30/2026	04/30/2026

Sobre la compañía

Nurix Therapeutics, Inc.

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton’s tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in Brisbane, California.

Fuente - Link

Competidores

BBOT EYPT FTRE KOD KURA PHAT SEPN TNGX URGN XNCR

Tamaño = capitalización · color = línea del gráfico

Rendimiento de peers · 1A

Top performers + empresa seleccionada

Ultimas Noticias

Nurix Therapeutics to Participate in Upcoming September Investor Conferences

BRISBANE, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that Company management will participate in fireside chats at the following investor conferences: Wells Fargo Healthcare Conference Tuesday, September 8, 2026, at 3:00 p.m.

GlobeNewsWire

Nurix Therapeutics: Roche Has Changed The Economics Of The Bull Case

Nurix secures a transformative Roche partnership, gaining $700M upfront, 50% U.S. profit share, and 60% Roche-funded global development for bexobrutideg. NRIX's financial runway is extended to ~3.5 years, reducing near-term dilution risk and enabling multi-indication expansion without sacrificing U.S. economics. Bexobrutideg's Phase 1 data show high response rates in CLL/SLL, with a pivotal Phase 3 trial aiming to demonstrate superiority over pirtobrutinib.

Seeking Alpha

Nurix Therapeutics Announces Appointment of Wes Burwell as Chief Human Resources Officer

BRISBANE, Calif., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein degradation medicines for patients with cancer and inflammatory diseases, today announced that Wes Burwell has joined Nurix as its Chief Human Resources Officer (CHRO).

GlobeNewsWire

Nurix Therapeutics (NASDAQ:NRIX) Reaches New 1-Year High After Analyst Upgrade

Nurix Therapeutics, Inc. (NASDAQ: NRIX - Get Free Report)'s stock price hit a new 52-week high during trading on Tuesday after Royal Bank Of Canada raised their price target on the stock from $33.00 to $36.00. Royal Bank Of Canada currently has an outperform rating on the stock. Nurix Therapeutics traded as high as $26.04 and

Defense World

Nurix Announces $10 Million Milestone Payment Associated with Initiation of a Phase 1 Clinical Trial of a STAT6 Degrader

Oral STAT6 degrader advances into clinical development for type 2 inflammatory diseases Nurix has earned approximately $139 million to date under its collaboration with Sanofi and remains eligible to receive approximately $453 million in future milestones associated with the STAT6 program, as well as potential royalties, and retains a U.S. co-development and co-promotion option BRISBANE, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that it has earned a $10 million milestone payment following the initiation by its collaborator, Sanofi, of the Phase 1 first-in-human clinical trial of SAR448272/NX-3911, an oral STAT6 degrader.

GlobeNewsWire

Sorpresas de ganancias

Período	Estimado	Real	Sorpresa
2026-04-08	-0.76	-0.79	-0.03
2026-01-28	-0.84	-0.82	0.02
2025-10-09	-0.84	-1.03	-0.19
2025-07-09	-0.71	-0.52	0.19
2025-04-08	-0.72	-0.67	0.05
2025-01-28	-0.67	-0.75	-0.08
2024-10-11	-0.67	-0.67	0
2024-07-11	-0.66	-0.71	-0.05
2024-04-10	-0.8	-0.76	0.04
2024-02-15	-0.51	-0.77	-0.26
2023-10-12	-0.69	-0.68	0.01
2023-07-13	-0.63	-0.45	0.18